ReviewFrontiers in pharmacology2026
Beyond angiogenesis: the paradoxical emerging pro-tumorigenic role of Thrombospondin-2.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment is a complex ecosystem where the extracellular matrix serves as a dynamic signaling hub and regulates tumorigenesis. Thrombospondin-2 (THBS2), a matricellular extracellular matrix protein, has traditionally been regarded as an inhibitor of angiogenesis. However, emerging evidence reveals a pleiotropic and paradoxical pro-tumorigenic role of THBS2 in several malignancies. THBS2 has been identified as a multifaceted regulator of critical mechanisms driving cancer progression including angiogenesis induction, vasculogenic mimicry, sustained proliferation, invasion, metastasis, phenotypic plasticity, and immune suppression in aggressive cancers. By modulating diverse signaling pathways, especially the PI3K/AKT/mTOR axis, remodeling the collagenous architecture of the extracellular matrix, and formation of non-endothelial vascular channels, THBS2 supports tumor progression and metastasis. This minireview encompasses current research regarding the emerging molecular mechanisms by which THBS2 regulates pro-tumorigenic functions and discusses its role in resistance to therapy. The diagnostic and prognostic value of THBS2, particularly in aggressive cancers, underscores the need for the development of novel therapeutics specifically targeting this deregulated protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.